Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of 15d-PGJ2 medicine

A 15d-pgj2, new-purpose technology, applied in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve problems such as poor response to UDCA, limited curative effect, and limited curative effect of cholestatic liver disease

Inactive Publication Date: 2019-06-07
HEFEI UNIV OF TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

UDCA is effective for most PBC, but there are still a considerable number of PBC patients who do not respond well to UDCA
In addition, UDCA has very limited efficacy on other types of cholestatic liver diseases, such as basically ineffective on PSC patients
Although the drugs for the treatment of PBC also include TUDCA (TUDCA is the combined form of taurine and UDCA, mainly for patients with poor response to UDCA) or S-adenosyl-L-methionine (S-adenosyl-L-methionine), glucocorticoids Combined with other immunosuppressants, fenofibrate (fenofibrate) and UDCA, but the efficacy of the above-mentioned drugs is still limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of 15d-PGJ2 medicine
  • New application of 15d-PGJ2 medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] The embodiments of the present invention are described in detail below. This embodiment is implemented on the premise of the technical solution of the present invention, and detailed implementation methods and specific operating procedures are provided, but the protection scope of the present invention is not limited to the following implementation example.

[0011] Wild-type C57BL / 6J mice (8 weeks old) were randomly divided into four groups: control group (Vehicle), model group (ANIT group), prevention group (Pre-15d+ANIT group), treatment group (15d+ ANIT group). Pre-15d+ANIT group mice were subcutaneously injected with 15d-PGJ for 3 consecutive days 2 (dissolved in DMSO, the dose is 1 mg / kg body weight), and the other groups were subcutaneously injected with the same amount of DMSO. On the fourth day, the ANIT group, the Pre-15d+ANIT group, and the 15d+ANIT group were given a single dose of ANIT (dissolved in olive oil, 80 mg / kg body weight), and the control group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a new application of 15d-PGJ2 medicine used for preventing and / or treating cholestatic liver disease.

Description

technical field [0001] The present invention relates to a kind of 15d-PGJ 2 New uses of drugs. Background technique [0002] Cholestasis refers to the abnormal formation, secretion, and excretion of bile acids caused by various reasons inside and outside the liver. It cannot flow into the duodenum normally and enters the blood. Cholestasis promotes liver damage. If cholestasis lasts for more than 6 months, it becomes chronic. Cholestasis. Hepatobiliary diseases with various reasons leading to cholestasis as the main manifestation are collectively referred to as cholestatic liver disease. The clinical manifestations are itching, fatigue, dark urine, jaundice, etc. It is often asymptomatic in the early stage, but the levels of ALP (alkaline phosphatase, alkaline phosphatase), γ-GT (γ-glutamyl transferase, γ-glutamyl transferase) and total bilirubin (total bilirubin) in serum increase, and the disease Hyperbilirubinemia, liver fibrosis, and liver cirrhosis develop in the mid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5575A61P1/16
Inventor 韩际宏段亚君李家琪杨潇潇陈元利
Owner HEFEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com